Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis is made using evaluated clinical criteria. Disease activity is best measured with a composite score assessing both objective signs and subjective symptoms, such as SCORAD. The management of AD must consider the clinical and pathogenic variabilities of the disease and also target flare prevention. Basic therapy includes hydrating topical treatment, as well as avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment of visible skin lesions is based on topical glucocorticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus. Topical calcineurin inhibitors are preferred in sensitive locations. Tacrolimus and mid-potent steroids are proven for proactive therapy, which is long-term intermittent anti-inflammatory therapy of the frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is indicated for severe refractory cases. Biologicals targeting key mechanisms of the atopic immune response are promising emerging treatment options. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) may diminish pruritus, but do not have sufficient effect on lesions. Adjuvant therapy includes UV irradiation, preferably UVA1 or narrow-band UVB 311 nm. Dietary recommendations should be patient specific and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. 'Eczema school' educational programmes have been proven to be helpful for children and adults.
Introduction and definitions
Atopic dermatitis (AD, atopic eczema, eczema) is a non-contagious inflammatory, chronically relapsing, and intensely pruritic skin disease occurring often in families with atopic diseases (atopic dermatitis, bronchial asthma and/or allergic rhino-conjunctivitis). AD is an eosinophilic/spongiotic inflammation of the skin with characteristic age-dependent distribution patterns and morphology of lesions. With a prevalence of 2-5% in young adults and up to 20% in children, AD is one of the most common skin diseases. The varying etiologic concepts of this disease are mirrored by the different names that are or have been used, such as 'neurodermatitis', 'neurodermitis', 'endogenous/constitutional eczema'.
Atopy can be defined as familial hypersensitivity of the skin and the mucosa to environmental substances, associated with increased production of immunoglobulin E (IgE) or altered pharmacologic reactivity. 5 Another definition for atopy, restricted to IgE production, is: 'a personal or familial tendency to produce IgE antibodies in response to low doses of allergens, usually proteins, and to develop typical symptoms such as asthma, rhinoconjunctivitis or eczema/dermatitis'. 6 The ETFAD defines atopy as the 'familiar tendency to develop Th2 responses against common environmental antigens', which keeps both IgE-associated, extrinsic and non-IgE-associated, intrinsic subtypes 7 within the definition of atopy, and cuts the need for mind and tongue twisting neologisms such as 'non-atopic atopic dermatitis'. The atopic diseases are genetically linked, and the concordance in monozygotic twins is 80% vs. 30% in dizygotic twins. 8 Described genetic polymorphisms in AD involve mediators of atopic inflammation on different chromosomes, some of these are also relevant for respiratory atopy. The strongest association has been shown with mutations in the filaggrin gene also associated with ichthyosis vulgaris, highlighting the predisposing barrier defect in AD patients. 9 Concomitant ichthyosis vulgaris can be diagnosed clinically and increased palmar hyperlineary is a simple and good indicator of filaggrin mutations. 10 In the first months of life, a yellowish layer of seborrhoeic, crusted scales on the scalp, known as 'cradlecap', may be the first presentation of AD, and can be treated with emollients only. The disease may then spread to the face, with middle face sparing, and to the extensor surfaces of the arms and legs of toddlers, sometimes showing extensive oozing and crusting. Later on, eczematous involvement of flexures, neck and hands predominates, accompanied by dry skin. The skin barrier dysfunction is reflected by an increased transepidermal water loss. Lichenification is the result of scratching and rubbing, frequently at night time. In adults, the prurigo type of AD is associated with predominant excoriated nodular lichenified lesions. Exacerbations often start as increased itch without visible skin lesions, followed by erythema, papules and infiltration. As histopathologic features are not specific for AD, routine histology is not a useful tool for diagnosing AD, but may help to rule out other important disorders such as cutaneous lymphomas in adults.
In the absence of a specific diagnostic laboratory marker, the diagnosis of AD is made clinically. The diagnostic power of an experienced clinician is superior to all diagnostic criteria available, but standardized criteria are needed for epidemiological research, as well as for inclusion criteria for clinical trials. Most diagnostic criteria are based on cutaneous signs of atopy. 5, 11 Hanifin and Rajka's criteria include: pruritus, typical morphology and distribution, chronic or chronically relapsing course, and atopic personal or family history (3 of 4 necessary), in addition to three minor criteria among a list of 21. 11 According to the UK working party criteria, itchy skin changes have to be diagnosed in the last 12 months, in addition to at least three of the following criteria: onset of the disease under the age of 2 years, history of involvement of skin folds, generalized dry skin, other atopic diseases, and visible flexural eczema. 12 Management of acute exacerbations (flares) of AD is a therapeutic challenge, as it requires efficient short-term control of acute symptoms, without compromising the overall management plan that is aimed at long-term stabilization, flare prevention and avoidance of side-effects. Exacerbation may sometimes uncover relevant provocation factors, such as other allergies or infection. Consequently, the initial workup must include a detailed inquiry on the circumstances of the flare, and a careful dermatologic examination including lymph nodes, orifices and all skin folds. Professional attitude in face of exacerbated disease is setting the stage for future compliance. Patients often have their own beliefs about the origin of their flare, but disparaging remarks at this time will only increase patient or parental frustration with medicine. Patient fears regarding treatment sideeffects must be taken seriously with a constructive attitude.
Definition of management descriptive items
The chronic, relapsing nature of AD causes difficulties to propose and explain long-term management strategies. Recent clinical trials addressing this issue have shown that there is a need for consensus definitions for management procedures, i.e. the new 'proactive treatment' compared to 'reactive treatment'. 13 There is a parallel need for health authorities to understand the claims of the industry for new products and reimbursement issues. The notion of intolerance or resistance to treatments is difficult to delineate except in case of well-demonstrated contact allergy leading to localized AD flares, but is a clinically meaningful soft term for inadequate AD improvement using potent topical corticosteroids (TCS) with intolerable long-term side-effects. As quantitative rules for prescription of topicals are in general not applied (the amount of active products -mg/surface unitimportant to prevent side-effects and assess efficacy, is rarely included in trials), it is difficult to refer to an upper limit to define resistance. As both objective signs and subjective symptoms, such as itch and sleeplessness, contribute to clinical severity, the overall disease activity is best measured with a composite score assessing both objective signs and subjective symptoms, such as the SCORAD.
14 Mild AD corresponds to SCORAD levels below 25
and severe AD to SCORAD levels above 50.
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The term of flare is clinically meaningful, but difficult to delineate. 16 Repeated measurements and arbitrary cut-off of an existing severity scale, such as SCORAD, 14 measured at sequential intervals by physicians have been used most frequently in the past. 16 The definition of flares based on intensity scoring is difficult because the level of tolerance to pruritus can vary on a large scale of magnitude. Some patients with highly lichenified lesions report moderate pruritus or insomnia. The basal level of medication should be taken into account to measure variations or flares. Kinetics of variation in symptoms might be considered, but is practically difficult to monitor, except in case of use of a patient-oriented validated scoring system such as the PO-SCORAD. 17 A valid, reliable and feasible flare definition acceptable for all clinical and research settings is still not consented.
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A recently favoured, behavioural definition of flare is 'acute, clinically significant worsening of signs and symptoms of AD requiring therapeutic intervention' (see Table 1 for ETFAD definition proposals). Disease stimuli such as Herpes simplex and Staphylococcus aureus infection, food-or aero-allergens or stress require different specific therapy and may modulate the response to baseline and anti-inflammatory treatment. There is no consensus on the diagnosis of an infectious flare due to S. aureus, except in case of clear-cut clinical evidence of impetiginization.
Maintaining a good quality long-term remission is a shared objective in chronic disorders. A widely accepted, uniform nomenclature would help to compare data. Long-term remission without lesions and treatment is usually synonym of cure, but the time without intervention that may correspond to such a situation has still to be defined. Remission achieved by the avoidance of irritants and allergens with sole emollient use is not comparable to remission under immunosuppressive agents or biologics. (Table 1) Other proposals come from asthma management (weeks with complete control/weeks with good control), or from pragmatically oriented judgement (increase in treatment, medical visit or call). 18 Kaplan-Meier diagrams comparing flare-free percentages of study populations using study drug and control for 1 year (or at least 3 months) is a clinically meaningful visualization for flare prevention studies. Data extraction of 'percent patients flared at study end' from treated patients only may produce misleading meta-analysis results, 19 whereas prolongation of time to first flare in 50% of treated vs. untreated patients, or comparing the percentage of flare-free patients at a fixed time (e.g. 12 weeks) is recommended.
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Basic therapy for atopic dermatitis and skin care
Atopic dermatitis is a chronic condition. Therefore, treatment has to be planned with a long-term perspective and special attention must be given to long-term safety aspects.
Cleansing
The skin must be cleansed thoroughly, but gently and carefully to get rid of crusts and mechanically eliminate bacterial contaminants in the case of bacterial superinfection. Cleansers with or without antiseptics in non-irritant and low allergenic formulas may be used, and are available in various galenic forms such as syndets or aqueous solutions. As the duration of action of some antiseptics is very limited, mechanical cleansing is probably more important. 21 The pH should be in a physiological cutaneous range around 5-6. In infants, it is easier to perform this first stage of gentle cleansing of skin on the nappy mattress rather than directly in the bath tub. A further cleansing followed by a rapid rinse is performed in the lukewarm bath. The short duration of the bath (only 5 min) and the use of bath oils (2 last minutes of bathing) are aimed at avoiding epidermal dehydration. European experts had recommended to bath no more than three times weekly especially in newborns, 22 but a recent prospective trial comparing twice weekly vs. once daily bathing found that the bathing frequency is unimportant as long as hydration of the skin is achieved. 23 Topical emollients are preferentially applied directly after a bath or a shower following gentle drying when the skin is still slightly humid. 21 Although bathing seems very important, there is lack of good evidence to prove its effectiveness.
Emollient therapy
AD is associated with skin barrier anomalies that facilitate an easier allergen penetration into the skin with an increased proneness to irritation and subsequent cutaneous inflammation. A lack of important stratum corneum intercellular lipids and an inadequate ratio between lipid compounds (cholesterol, essential fatty acids, ceramides) as well as filaggrin defects 9 enhance transepidermal water loss leading to epidermal microfissuring, which may also cause direct exposure of Langerhans cell dendrites as well as nerve endings to the environment. A better molecular and biochemical knowledge on this predisposing background should provide access to barrier improving topical agents. The cost of high-quality allergy-safe emollient therapies often restrict their use because such therapies are considered to be non-prescription drugs and the quantities required are usually high (30 g per day or 1 kg/month in adults). 3 The direct use of emollients on inflamed skin is poorly tolerated and it is better to treat the acute flare first, as outlined below. Using a barrier ointment, which can also be used as bath oil and shower gel, seems optimal (Fig. 1) . Hydration of the skin in adults is usually maintained by at least twice daily application of moisturizers containing glycerol or, if tolerated, approximately 5% urea. The latter is known to significantly reduce the risk of AD relapse. 24 Emulsions or micellar solutions as well as bath oils may also help to reduce the flares. Use of emollients improves dryness and subsequently pruritus during the treatment of AD and especially improves the barrier function. There is some evidence-based proof for the use of emollients regarding onset of AD in a risk population, 25 for a corticosteroid-sparing effect and for improvement of the dryness of the skin. New developments in emollients are the incorporation of active compounds that repair the barrier function or influence the microbiome of atopic dermatitis with bacterial lysates from Aquaphilus dolomiae or Vitreoscilla filiformis species. 26 Emollients containing potentially allergenic plant proteins such as peanut, oat or wheat should be avoided in the most vulnerable age group before the age of 2 years.
27 Table 1 Definitions of descriptive items for the management of AD Flare Acute, clinically significant worsening of signs and symptoms of atopic dermatitis requiring therapeutic intervention.
Intolerance to topical treatment
Patient's opinion after at least 2 weeks of therapy with a new topical treatment because of worsening of lesions or any difficulty to apply the drug (ointment not supported, pain, burning or any uncomfortable sensation).
Items
Measurable disease related features, can be either or both signs and symptoms.
Proactive therapy Long-term, low-dose intermittent application of anti-inflammatory therapy to the previously affected skin, together with an ongoing emollient treatment of unaffected skin.
Remission/Control
Period without flare of at least 8 weeks without anti-inflammatory treatment (irritant/allergen avoidance and emollient use not included).
• Complete remission: if using basic treatment (avoidance, emollients)
• Incomplete remission: if using moderate treatment, topical corticosteroids or calcineurin inhibitors less than 30 g ⁄ month in children and less than 60 g ⁄ month after 15 years of age
• Control: if using major treatment including phototherapy and/or immunosuppressants
Severity of disease
The overall impact of signs and symptoms of AD on a patient, which requires assessment with a composite score.
• 
Treatment of atopic dermatitis: children
• For every phase, additional therapeutic options are given
• Add antiseptics / antibiotics in cases of superinfection
• Consider compliance and diagnosis, if therapy has no effect chemicals is frequently found in AD. Diagnosis of the disease has to be distinguished from diagnosis of individually relevant trigger factors. In some centres, exploration for allergic disease is limited to severe cases without response to classical topical treatment.
Food allergens
About one-third of children with a moderate to severe AD has an associated food allergy. 29 It is a common misconception that food allergy would be causative in the setting of AD. Parents must be warned that general elimination diets are not recommended, 30 and can be detrimental. 31 In AD children with proven food allergy, good skin care is also the mainstay of treatment, but identifying and avoiding trigger factors is important. 30 It is thus important to differentiate causality, coexisting disease and disease modifiers. Sensitizations to foods can be investigated by means of in vivo tests (skin prick tests, prick-prick tests) and in vitro tests (serum specific IgE). A positive test will reflect sensitization, but may have poor correlation with clinical allergic responses. 32 In addition, atopy patch tests proved to be useful for studying delayed food-related skin responses. 33 Skin prick test (SPT) with food allergens (i.e. cow 0 s milk, eggs, wheat, soy, peanut) is suggested in children <5 years with moderate to severe AD, that is persistent in spite of optimized management and topical therapy. Food allergy is less common in older age groups. Tests are recommended when food allergy is suspected.
In vitro tests are valuable when SPT cannot be applied because of urticaria factitia (dermographism), UV-and drug-induced skin hyporeactivity, eczema at the test site, lack of compliance for SPT in infancy. Moreover, in vitro specific IgE to food allergens give better quantitative data for the grade of sensitization, which helps to estimate the probability of the risk of a clinical reaction and offers the opportunity to test single recombinant allergens, which may have a better diagnostic specificity than testing with food extracts for some foods.
The atopy patch tests (APT) for food allergens may be performed with self-made food material using large test chambers for 48-72 h, but these test materials are not standardized. 34 Although immediate-type reactions are associated with SPT positivity, delayed ones are related to positive responses to APT. However, food challenge is not replaced by patch testing. So far, APT have demonstrated to improve the accuracy of skin testing in the diagnosis of allergy to cow 0 s milk, egg, cereals and peanuts in AD patients. [35] [36] [37] In spite of good APT data published, there are currently no approved test substances available. The best method to prove clinically significant allergy is the double-blind placebo-controlled food challenge. In clinical reality, elimination and reintroduction of a certain food after a reliable history can be sufficient. Oral challenging of AD patients with foods may induce early reactions such as urticaria, gastrointestinal or respiratory symptoms occurring within 120 minutes after allergen administration, or eczematous late phase responses after 2-48 h. After oral food challenge, about 45% of challenges resulted in both immediate and delayed reactions, and 12% show worsening of eczema only. 38 The personal history has a low predictive value (30%) for oral challenge induced late reactions, as opposed to 80% for immediate reactions. 38 
Aeroallergens
Clinical observations and experimental studies indicate that aeroallergens are relevant trigger factors in AD patients. 39 Exacerbations of eczematous lesions after skin contact or inhalation have been described, but studies on allergen avoidance strategies show conflicting results. 40 Routine diagnostic workup of suspected allergy to aeroallergens includes detection of specific IgE by means of skin prick tests or in vitro IgE assays. However, both techniques have a low predictive value. APT with aeroallergens targets the cellular component of AD, 41 and has been performed with house dust mites, pollen and animal dander, obtaining different positivity rates (15-100%) according to patch test materials and modalities. 33 On the basis of the history of aeroallergen-triggered AD flares, APTs proved to have higher specificity and lower sensitivity than the above-mentioned tests, 41 and may detect sensitization in skin prick test negative, 'intrinsic' AD patients. 42 The availability of standardized aeroallergen preparations for APT from different manufacturers has declined during the last 5 years. The reimbursement situation for APT is inappropriate in most countries, which further reduces its routine use. 33 As still no feasible standard procedure for provocation of eczema in aeroallergen-mediated AD exists, specific avoidance strategies should be considered in highly sensitized patients with chronic moderate to severe disease (Table 2) .
Contact allergy
Contact allergy may be detected in 40-65% of AD patients and cause worsening of their skin lesions. 43 Therefore, patch testing is recommended in AD patients with recalcitrant disease, atypical localization or aggravation without known cause, especially when systemic intervention is considered. 44 Emulsifiers, fragrances, preservatives, corticosteroids and other components of topical treatment preparations are the most relevant substances to be tested. 43, 45 Children with AD who have long-lasting hand and/or foot dermatitis should always be patch tested to evaluate if they have a relevant contact allergy and allergic contact dermatitis. 46 AD patients run a significant risk of developing occupational contact dermatitis. Atopy amplifies the effects of irritant and allergen exposure in hairdressers, cleaners, metalworkers, mechanics and nurses, where hand eczema is a very common disease. 47 Preventive strategies should be developed and opti-mized to reduce the incidence of occupational dermatitis in AD patients.
Topical anti-inflammatory treatment
Effective topical therapy depends on three fundamental principles: sufficient strength, sufficient dosage and correct application. 2 Topical treatment should always be applied on hydrated skin, especially when using ointments. If emollients and antiinflammatory topical preparations must be applied to the same location, the cream formulation should be applied first and only 15 min later the ointment formulation. Even without wet wraps, topical therapy is time consuming: patients should plan 30 min for one session. One well-conducted treatment per day is usually sufficient; oozing AD may require a few days with higher treatment frequency. 12 
Wet-wrap treatment
Children and adults with acute, oozing and erosive lesions, sometimes do not tolerate standard topical application, and may first be treated with 'wet wraps' until oozing stops. 21 Wet-wrap dressings with diluted TCS are applied for up to 14 days (usually up to 3 days) and are a safe crisis intervention treatment with temporary systemic bioactivity of the corticosteroid as the only reported serious side-effects. 48, 49 Specialized nurse care is necessary to monitor the disease and to guide parents and patients, a combination with eczema schools is helpful.
Corticosteroids
TCS are the most widely used anti-inflammatory treatment option, applied on inflammatory skin according to needs (pruritus, sleeplessness, new flare). Numerous substances are available in a variety of formulations. 50 TCS are grouped by potency according to Niedner from mild (group I) to superpotent (group IV). 51 Potent and very potent TCS (group III and IV) are more likely to cause depression of adrenal function than group I (mild) and II (moderate strength) treatments, but their systemic effects will decrease more quickly due to more rapid restitution of the skin barrier. 52 Prescribers should know this classification, as they should know that the US-American classification is different and ranges from VII (weakest) to I (strongest). Superpotent TCS (group IV) are not recommended for AD treatment, especially not in children. The risk of inducing side-effects is lower with the use of the relatively new topical steroids with short half-life, such as prednicarbate, fluticasone and momethasone. A well-conducted systemic AD treatment may be safer and more advisable than prolonged use of high potency TCS for AD. For routine treatment of flares once daily application of a potent TCS is sufficient, usually for 3-6 days. With mild disease activity, a small amount of TCS twice to thrice weekly (monthly amounts in the mean range of 15 g in infants, 30 g in children and up to 60-90 g in adolescents and adults), associated with a liberal use of emollients generally allows a good maintenance with SCORAD values below 15-20. Such monthly amounts of Diagnosis and treatment of atopic dermatitis even more potent TCS usually do not have adverse systemic or local effects. The most constructive way to spare TCS and avoid steroid-related side-effects is not to spare them during acute flares, but through consequent baseline emollient skin care combined with early anti-inflammatory intervention in order to stabilize the disease, and prevent treatment-intensive flares. 53 Itch is a key symptom for evaluation of response to treatment, and tapering should not be initiated before itch has disappeared. The transition from daily application to the maintenance phase is not standardized. Some favour gradual tapering to avoid withdrawal rebound, and tapering strategies consisting either in using a less potent TCS on a daily base, or keeping a more potent one while reducing the frequency of application. However, the twice weekly application scheme of potent TCS has been shown to limit flares in RCTs (see proactive treatment section).
Topical calcineurin inhibitors
Topical calcineurin inhibitors (TCI) show good anti-inflammatory and antipruritic effects, while lacking many adverse effects of TCS such as skin atrophy. The choice for a substance class should be made for each patient individually, considering the sensitivity of treated areas for side-effects, as well as economic aspects. 50 The two steroid-free TCI, tacrolimus ointment and pimecrolimus cream, are licensed for topical AD treatment. The anti-inflammatory effects result from an inhibition of proinflammatory cytokine production from T cells, whereas their anti-pruritic effects are attributed to an inhibition of mast cell degranulation. 54 The efficacy of both formulations has been demonstrated against placebo in clinical trials for short-term and long-term use. [55] [56] [57] [58] In addition, proactive tacrolimus ointment therapy has been shown to be safe and effective for up to one year in reducing the number of flares and improving the quality of life in adult patients and children. 59, 60 The antiinflammatory potency of 0.1% tacrolimus ointment is similar to a TCS with intermediate activity, 61 while the latter is clearly more active than 1.0% pimecrolimus cream. 62 Safety data of both TCI have been reported in many clinical trials, demonstrating the safety of these drugs in daily routine use. 63, 64 The most frequently observed side-effect is a transient warmth sensation or transient burning at the application site during the first days of application. 55, 62 It starts about 5 min after each TCI application and may last up to one hour, but intensity and duration typically decrease with twice daily application within 1 week to zero. 65 The efficacy of long-term monotherapy with tacrolimus ointment has been shown in children and adults. 61, 73 Less data are available for children under 2 years of age. 74 Pimecrolimus cream has been studied in infants and children in a combination regimen with TCS, 75,76 the latter being given if a flare occurred.
Both TCI are approved in the EU from 2 years of age and above, but off-label use in lower age is common. 64 High-quality longterm safety data has been published from a 4 year tacrolimus and a 5 year pimecrolimus study.
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Tar Topical application of coal tar is one of the oldest therapies for AD, with long-standing but declining clinical use and moderate efficacy. Coal tar may restore filaggrin expression and counteract the Th2-mediated downregulation of skin barrier proteins by aryl hydrocarbon receptor (AHR) activation and STAT6 dephosphorylation, thus diminishing spongiosis, apoptosis, and CCL26 expression in AD lesions. 78 The cosmetic acceptance of tar preparations is poor, but tar preparations may be considered in selected cases, e.g. those with lichenification. The use in infants is controversial.
Proactive therapy
By tradition, anti-inflammatory topical therapy has been administered to lesional skin only and has been stopped or tapered down once visible lesions were cleared. This traditional, reactive approach has in the last decade been complemented by the proactive treatment concept, which is defined as a combination of predefined, long-term, low-dose, anti-inflammatory treatment applied to previously affected areas of skin, in combination with use of emollients on the entire body and a predefined appointment schedule for clinical control examinations. 13 The proactive, usually twice weekly topical treatment of the previously affected areas is started only after all visible lesions have successfully been treated, in addition to daily ongoing emollient therapy for both previously affected and unaffected skin. 20 Clinical trial data are available for the steroid products methylprednisolone aceponate and fluticasone propionate for up to 3 months, as well as for tacrolimus ointment for up to 1 year, 59, 60, 79, 80 and recently been reviewed. 20 As a rule, barrier disruption is lower with proactive therapy than with daily application, as it is lower with TCI than with TCS. 81 85 and there may be a reduced antigen presentation by an increased phototherapy-induced thickness of the stratum corneum leading to a milder AD. 86 Phototherapy is frequently used for treatment of AD, especially for treatment of the chronic phase in adults. 83 When prescribed, phototherapy is usually a part of a total treatment plan, i.e. a second-level treatment used especially in adults and much less in children. Due to theoretical concerns and limited data on the use of phototherapy in children with AD, phototherapy is not a common therapeutic consideration in prepubertal children. As a rule, phototherapy is not indicated in the acute stage of AD (except UVA1, which is also effective in managing AD flares), but is more apt to treat chronic, pruritic, lichenified forms, and should not be prescribed in those patients who experience a worsening of their dermatosis during sun exposure. In practice, the choice of a different UV treatment is limited by the availability of the phototherapy equipments: e.g. UVA1 is expensive to buy and to maintain. The biggest drawbacks of UV therapy are that the patient must travel between 3 and 5 times per week per 6-12 weeks to a site that offers this therapy. In addition, UV light does not effectively treat hairy areas such as scalp and skin folds.
Beside visible sun light (VSL), photo(chemo)therapy for AD may be useful with different artificial light sources: broad spectrum UVB (280-315 nm), narrow band UVB (311-313 nm), broadband UVA (UVA-BB) (315-400 nm), UVA1 (340-400 nm), UVA1 cold light (with seawater baths plus UVB (balneophototherapy) and psoralen plus UVA (PUVA). UVA1 phototherapy can be applied as moderate-dose (MD) (50 J/cm 2 ) and low-dose (LD) (10 J/cm 2 ) regimen, whereas high dose (HD) (130 J/cm 2 ) is not recommended anymore for AD treatment. New devices such as 308 nm monochromatic excimer light are experimental and can treat only limited surfaces. 87 Though blue light has been used for AD in an uncontrolled trial, 88 treatment with longer wavelengths has not been carefully studied for AD and is therefore not recommended. UV treatments should not be started too early or in oozing lesions, as this will often result in a poor treatment outcome. Patients should instead be treated with a standard regimen of emollients, TCS and antibiotics for some days before starting UV treatment. Combined use of TCI with UV is a matter of debate, even if the initial warnings of an increased skin cancer risk have not been substantiated. 63 In short, taking into account the individual tolerability, narrow band UVB has been indicated for chronic-moderate forms of AD and is currently preferred to broadband UV because it is less erythemogenic. High-dose UVA1 has been used for more severe phases, but is not recommended anymore. Medium-dose UVA1 appears to be similar in terms of efficacy as narrow band UVB. 89 TCS and emollients should be considered at the beginning of phototherapy to reduce a possible flare-up. UV can also be combined with a prior (oral or topical) administration of photosensitizing drugs (psoralens): the socalled PUVA (photochemotherapy). All UV treatments and, even more, photochemotherapy, pose a long-term risk for development of skin cancer, together with the proven premature ageing of the skin. 83 Photochemotherapy is not the first choice for AD treatment due to its proven carcinogenicity and the fact that most AD patients are young. During photochemotherapy, patients must wear UVA-blocking sunglasses also after treatment for 1 day when exposed to sunlight because psoralens are eliminated slowly. While simple UV regimens are generally well tolerated (a transient sensation of warmth should be considered normal), oral PUVA has a number of side-effects, which may include nausea, headache, fatigue, burning skin, itching and irregular skin pigmentation as well as an increased risk of skin cancer, 83 so the risk/benefit ratio of this treatment must be carefully weighted. The risk/benefit ratio of topical PUVA for palms and soles is usually favourable.
In conclusion, phototherapy can improve, and even clear, AD; it can decrease bacterial colonization and reduce the strength and/or the amount of topical antinflammatory drugs needed, but the beneficial effects vary from person to person.
Allergen-specific immunotherapy
The efficacy and safety of allergen-specific immunotherapy (ASIT) in AD has been shown in case reports, smaller cohort studies and larger multicentre trials on house dust mite immunotherapy. 90 
Antihistamines
Systemic antihistamines targeting the histamine 1 receptor (anti-H1R) are used in acute AD flares against itch, however, controlled studies have not shown any effects on AD scores but a protective or inhibiting effect on associated urticaria in AD patients. 92 Antihistamines may be tried to decrease pruritus and permit sleep during flares, but may affect sleep quality. In this setting, the older sedative anti-H1R molecules such as hydroxyzine are considered more helpful than the newer less sedating anti-H1R-specific drugs. Long-term use in children is not recommended. Ongoing studies concentrate on the blockade of alternative histamine receptors such as H4R, which may be more important in AD. 93 
Antibacterial and antimycotic therapy
Some inherited defects in innate cutaneous immunity and transient acquired changes of local antimicrobial defence mechanisms in AD may explain the high rate of cutaneous colonization with Staphylococcus aureus (up to 90% in moderate to severe AD). 94 A recent study on the skin microbiome confirmed the increase in gene copies of S. aureus with a decrease in microbial diversity at the same time at the sites of AD. 95 Antibiotic eradication of S. aureus may therefore not always be an appropriate long-term strategy, especially with regard to the increasing prevalence of antibiotic resistance. 96 In general, topical antibiotics should not be used for longer periods in the treatment of AD. However, there is evidence for an association of S. aureus-derived superantigens and alpha toxin with disease exacerbation, 97, 98 supporting early observations that the density of S.
aureus colonization in AD is significantly correlated with clinical severity, 99 and that patients with severe AD may improve (but not be cured) by anti-staphylococcal treatment. 100 In general, improving AD with anti-inflammatory regimen (i.e. TCS, TCI, UV) will decrease S. aureus colonization. This led to the clinical concept that patients with high numbers of colonizing S. aureus can benefit from combination treatment with TCS and antibacterial treatment, 50 in most cases using topical antiseptics like chlorhexidine, octenidine and cristal violet 0.3%, or bathing in diluted sodium hypochlorite (ca. 100 mL of 5% household bleach per 100 L, a full tub of water) or potassium permanganate (ca. 100 mL of 1% KMnO4 stock solution per full tub of water). [101] [102] [103] [104] All lack good evidence and clinical experience is quite different across countries. Topical antiseptics are particularly recommended when acute flares of AD are associated with clinical signs of bacterial impetiginization, such as oozing, pustules and fissures. The clinical experience is quite different across countries. Sometimes this clinical picture may additionally justify systemic treatment with an oral antibiotic. 4 Apart from specific indications such as overt secondary infection or presence of beta-haemolytic streptococci, treatment of AD with antibiotics has no prolonged effect on clinical improvement and sparing of TCS 105 and should therefore not be recommended. The use of silver-coated synthetic textiles, of silk fabric with the durable antimicrobial finish, or of acid-coated textiles can reduce S. aureus colonization and AD severity. [106] [107] [108] The percutaneous absorption of silver ions from these textiles under reallife conditions is lower than the current reference dose. 109 Other secondary infections, such as yeast, dermatophytes and streptococcal infections have also been implicated as disease factors in AD. Intense, fleshy erythema in skin folds of children with a flare of AD may warrant a search for streptococcal skin infection. In general, signs of secondary infections should be treated if present. Ciclopiroxolamine is proposed for topical treatment of 'head and neck' AD, which is often associated with Malassezia sympodialis superinfection. 110 Systemic ketoconazole 111 and topical ciclopiroxolamine 112 have been shown to improve AD significantly within 4 weeks in placebo-controlled trials in patients with 'head-neck-shoulder dermatitis'.
Antiviral therapy
Viral infections are occurring more frequently in AD patients than in normal individuals, with a tendency to disseminated, widespread disease. The latter are named after the causative virus as eczema herpeticum, eczema molluscatum, eczema coxsackium or eczema vaccinatum. 113 
Eczema herpeticum
A disseminated, distinctly monomorphic eruption of dome-shaped vesicles, accompanied by fever, malaise and lymphadenopathy is suggestive for eczema herpeticum (EH). Physicians and patients should be aware of the symptoms, as unintentional anti-inflammatory instead of antiviral treatment may favour a progression from herpes simplex to EH. EH has been described following TCS and TCI therapy, but study data indicate that patients with severe, untreated AD, a high total serum-IgE and early onset of AD are at risk for EH, whereas pretreatment with TCS does not imply a risk. 114 The clinical diagnosis should be confirmed by PCR, electron microscopy or immunofluorescence tests if possible. A direct Tzanck smear is quicker, but not specific. The mainstay of EH therapy is prompt systemic antiviral chemotherapy with i.v. aciclovir. Eczema molluscatum AD patients, in particular children, may develop widespread eczema molluscatum (EM) with up to several hundred umbilicated small skin-colored papules. 113 Dermatoscopy of mollusca will show molluscum bodies. Although EM lesions resolve spontaneously, treatment speeds healing and prevents spreading by auto-and heteroinoculation. In addition to mild anti-inflammatory treatment, 115 limited numbers of lesions may be destroyed with a small curved forceps, removed by curettage, or destroyed by cryotherapy or carbon dioxide laser vaporization to limit autoinoculation. 113 Topical application of KOH, imiquimod or another topical immunostimulatory agent is an alternative.
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Impact on the children's quality of life and absence of resolution after 1 year could be indicators for treating patients.
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Systemic anti-inflammatory therapy
Resistance to well-conducted topical therapy is rare, so that oral immunosuppressive drugs should be limited to severe cases, both in children and adults, where the potential of topical treatments (or of patient compliance) and/or UV-light therapy has been exhausted. 44 In addition, oral immunosuppressive drugs can be useful to reduce the total amount of TCS in those patients needing daily potent TCS treatment of large body areas to control their AD. The following recommendations for systemic drugs are based on medical considerations, but these may differ from the legal licensing status that is not uniform in European countries. Before starting a systemic treatment, it is important to rule out potential trigger factors as type I allergies or contact dermatitis by allergy testing. The most frequently used oral immunosuppressive drugs in AD are systemic corticosteroids (SCS), cyclosporine (CyA), azathioprine (AZA), mycophenolate mofetil (MMF), enteric-coated mycophenolate sodium (EC-MPS) and methotrexate (MTX). 118 These may be used in two different treatment phases: In the induction phase for patients with acute severe exacerbations, drugs with a rapid onset of action such as CyA or a short course of SCS are needed. In the maintenance phase for patients with chronic severe disease, drugs with a slow onset of action such as AZA, MMF, EC-MPS or MTX are useful. A preliminary induction phase with a rapidonset-of-action drug may sometimes be needed.
Systemic corticosteroids
SCS are rapidly effective, but have a largely unfavourable risk/benefit ratio. 4 SCS should only be used for a few weeks for severe acute exacerbations due to the many long-term side-effects. A typical regimen for severe acute exacerbations would be methylprednisolone maximal 0.5 mg/kg/day for 1-2 weeks and tapering over 1 month. Short courses of SCS without adequate tapering can lead to high rates of relapse/rebound of the disease. 119 In severe chronic cases, starting of another oral immunosuppressive therapy while tapering the SCS should be considered. SCS must not be used for long periods of time due to significant risk of severe side-effects.
Cyclosporine A
CyA is frequently used and very effective for AD in both children and adults 4 and used at 3-5 mg/kg/day, divided into a morning and an evening dose. The dosage can usually be tapered after 6 weeks to 2.5-3 mg/kg in the maintenance phase. CyA has a narrow therapeutic index and requires a close follow-up for blood pressure and signs of renal impairment, even if clinically relevant serum creatinine increase seems less common than expected. 120 CyA is the only approved substance for systemic treatment of AD in adults in many countries. 4 CyA is not approved, but may be used for children or pregnant females. Treatment duration usually varies from 3 months to 1 year, but some patients tolerate much longer low-dose CyA treatment very well. 121 CyA is usually considered as the first-line option for patients requiring immunosuppressive treatment. 4 Azathioprine AZA has a slow onset of action, as the maximal clinical efficacy is reached after 8-12 weeks. A starting dose of 50 mg/day for 1-2 weeks is recommended in adults. Depending on acute adverse events such as gastrointestinal side-effects, liver enzyme elevation or haematological abnormalities, the dose can usually be increased to 2-3 mg/kg/day. Low thiopurine-methyltransferase (TPMT) activity is associated with an increased myelotoxicity of azathioprine, but TMTP activity screening tests can identify patients at risk before starting the treatment. 122 Longterm efficacy and safety data in AD patients are sparse, but may be derived from transplantation patients. AZA increased the risk of non-melanoma skin cancer and lymphoma in inflammatory bowel disease patients. 123, 124 AZA may be used in children. 125, 126 In pregnant females, AZA should only be used on strict indication.
Methotrexate
The maximal clinical efficacy of MTX is reached after 8-12 weeks, the recommended therapeutical doses are between 7, 5 and 25 mg once weekly in adults. Infections, gastrointestinal disturbances, and rarely, myelotoxicity may limit the use of MTX. However, MTX is often well tolerated, available for oral and subcutaneous administration and has been used for many years all over the world. Children with AD can be treated with MTX 10-20 mg/m 2 /week. MTX is about equally effective to AZA in adults and children. 127 MTX is hepatotoxic and teratogenic, and women of child-bearing potential must use effective contraception during therapy. Each MTX cycle should be followed by a folic acid substitution.
Mycophenolate mofetil
MMF at 2 g/day and EC-MPS at 1440 mg/day have a slower onset of action compared to CyA, but EC-MPS is as effective as CyA as maintenance treatment in patients with AD. 128 Mild gastrointestinal side-effects and haematological abnormalities are 
Intravenous Immunoglobulin
Intravenous immunoglobulins (IVIG) are considered as immunomodulatory substances. IVIG have been tried for both adults and children with severe, treatment refractory AD, but clinical trials did not indicate a high efficacy or quick onset of action despite the high cost of treatment. 134, 135 Therefore, IVIG may be considered as a last resort treatment in severe, treatment refractory AD in children only.
Immunoabsorption
Immunoabsorption for reducing high serum IgE levels in AD patients has improved AD signs and symptoms in parallel with a decrease in skin bound IgE and inflammatory cell numbers in a pilot study. 136 Currently, this treatment option is considered experimental.
Maternal exposure to oral immuosuppressive drugs during pregnancy and paternal exposure before fathering
The maternal benefit of oral immunosuppressive drugs in expecting AD patients must always be weighed on an individual basis against possible adverse effects such as spontaneous abortion, prematurity, low birth weight, adrenal insufficiency by maternal corticosteroid use, infections and teratogenicity. Treatment with CyA and SCS is well possible during pregnancy, but pregnancy does not improve the largely unfavourable risk/benefit ratio of SCS. Absolutely contra-indicated in pregnancy are MTX, Alitretinoin, MMF and EC-MPS; treatment with AZA is possible on strict indication and the dose of AZA should be halved.
The relationship of paternal use of oral immunosuppressive drugs before fathering and congenital abnormalities is less clear than the effects of maternal use. Although studies are often small and of poor quality, several guidelines recommend for men using AZA or MPA to adequately use contraceptive measures during treatment and for 3 months thereafter. 137 Fathering during MTX treatment is contra-indicated in Table 3 .
Biologics
The inflammation of AD is orchestrated by multiple resident and skin infiltrating cells and their products such as cytokines, chemokines and immunoglobulins. Targeting these cells, their products or receptors seems a reasonable therapeutic strategy. Although biologics have widely been used for other skin diseases, in individual AD patients or in small clinical trials, none of the biologics available in 2015 has been approved for AD therapy. 138, 139 The reduction of T-cell numbers and activation by alefacept and efalizumab resulted in improvement of AD signs and symptoms, 140, 141 but both drugs were taken from the market due to economical and safety reasons, respectively. Rituximab is an anti-CD20 antibody depleting B cells, which act as antigen presenting cells, promote T-cell activation and produce proinflammatory cytokines and IgE. Therapy of AD with rituximab resulted in a rapid reduction of skin inflammation in all patients with a sustained effect over 5 months in five of six patients. 142 Later reports stated a limited effect in patients affected by very severe AD. 143 Since the inflammation of AD is characterized by eosinophil infiltration, the depletion of eosinophils seemed a promising approach for AD treatment. A short-term therapy with two injections of the anti-IL-5 antibody mepolizumab (2 9 750 mg) lead to a rapid decrease in blood eosinophils, but only a moderate improvement of clinical symptoms. 144 Anti-TNF-alpha therapy may significantly reduce AD signs and symptoms including pruritus during induction therapy, but failed to achieve a long-term maintenance effect. 145 Severe exacerbations of AD upon anti-TNF-alpha therapy have also been reported. 146, 147 Blocking the IL-6 receptor pathway with tocilizumab resulted in a marked improvement of AD in severely affected patients, but led to severe infections in the patients. 148 The anti-IgE antibody omalizumab showed a significant decrease in SCORAD levels in some AD patients, 149 Dupilumab is a monoclonal antibody blocking the common alpha chain of the IL-4-and IL-13-receptor, and induces a rapid, marked improvement in signs and symptoms of AD including pruritus. 154 Noteworthy and in contrast to many other biologics, dupilumab-treated patients experienced fewer severe adverse events, and significantly less infections compared to the placebo upon 12-weeks monotherapy with dupilumab. 154 Many other mediators and receptors are of interest as potential therapeutic targets for AD treatment, and studies involving IL-4, IL-13, TSLP, IL-22, IL-25, IL-31, histamine, histamine receptors 1 and 4, may become available in the next years.
Vitamins and probiotics
The role of vitamin D and the vitamin D receptor (VDR) in AD has been studied in three single-center randomized placebo-controlled studies including a total of 142 patients. One study found a significant clinical effect, but concomitant routine treatment was allowed and not registered. 155 Better designed studies did not find a beneficial effect of Vitamin D supplementation on AD manifestations. [156] [157] [158] Hence, a supplementation of vitamin D is currently not recommended, neither for treatment nor for prevention in AD. Treatment regimens with probiotics aim to modulate the microflora in the gut in order to stimulate the immune response towards an allergy protecting, T helper 1 biased immune reaction. 159 There is some evidence now to suggest that probiotics are safe and moderately effective in preventing the onset of AD in children, with a decreased risk of approximately 20% in 3 years. 160, 161 However, uncertainties remain around how probiotics should be ideally delivered (in mothers before birth, in children after birth or both), for how long, and what exact strains should be used.
Specific considerations for children
The anatomical and pathophysiological peculiarities of children, such as an incomplete skin barrier, a higher surface/bodyweight ratio, and a less experienced immune system -together with the fact that many drugs effective for AD are not licensed for children -result in some special considerations and treatment rules for young AD patients, especially for those aged 2 years and younger.
The clinical presentation of infantile AD shows different predilection sites and a tendency towards exudative lesions, especially on the cheeks. Establishing a diagnosis of AD is not always straightforward in this age group because the classic diagnostic criteria cannot be applied. In early-onset severe AD (< 3 months), some primary immunodeficiency syndromes such as Omen syndrome, selective IgA-deficiency, Hyper-IgE-syndromes and Wiskott Aldrich syndrome, some genetic disorders with an impaired barrier function such as Comel-Netherton syndrome and peeling skin syndrome and some inherited metabolic The trigger factors for AD in young children include stress and conflicts in the family. Flares are associated with contact to non-familiar pets, swimming in chlorinated pools and direct skin exposure to wool and nylon textiles. 163 Food allergies triggering an exacerbation are more frequently found than in adults. In small children, cow's milk protein and hen egg are the most common relevant allergens, in adolescents, pollen-associated food allergens are more important. Food allergies in young children are often transient, making follow-up investigations necessary to assess the development of tolerance. 164 As most of the comorbidities of AD develop during childhood and adolescence, beside prevention measures, alertness and timely diagnostic work-up are necessary in that age segment to allow early recognition of atopic respiratory diseases and food allergies. Recently, attention-deficit hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD) have been identified as possible comorbidities of AD. 165 New insights into the pathophysiology of AD, especially concerning the impaired barrier function and the observation that intrinsic AD is more prevalent in infants than in adolescents and adults 166, 167 has promoted the hypothesis, that restoration of the skin barrier might be a valuable primary prevention measure to avoid sensitization and subsequent atopic diseases -recent data support this hypothesis. 25, 168 Regarding treatment of children with AD, management differs between countries. The principles of topical treatment are the same as in adults, but are adapted with respect to an increased absorption and altered surface to bodyweight ratio. The use of weaker TCS (class 1 and 2) in small children is common practice of many dermatologists and paediatricians. Especially critical areas in infants are the diaper area, the face and the scalp. An increased use of TCI to spare TCS is widely advocated due to the ever-increasing experience and long-term safety data with the substance class. 63 Attention should be paid to prescribe hypoallergenic topical preparations (emollients as well as anti-inflammatory drugs). Emollients and bath additives containing potentially allergenic proteins such as peanut or oat should be avoided in the most vulnerable age group before the age of 2. 27 In the perspective of long-term treatment of a chronic condition, ingredients known as common hapten allergens should also not be applied (e.g. lanoline, fragrances, allergenic preservatives). 169 Glycerol as moisturizer in emollients is better tolerated than urea in children under 5 years of age. Parent and child education ('eczema school') is an integrated part of AD management, and especially valuable to reduce AD symptoms. 170, 171 For the care of children in an outpatient setting, written treatment instructions may be very useful. Positive experiences have been reported with the 'Personalized Written Action Plan for Atopics'. 172 Systemic treatment for children is administered on a patient individual basis in severe cases, and there is no consented standard treatment for the substances or the duration. The most commonly used drug in Europe is CyA, followed by SCS and AZA. 173 Recently, low-dose MTX was shown to have a good safety profile 174 and an effectiveness comparable to CyA. 175 However, large controlled comparative studies are lacking. The only systemic drug licensed for the treatment of AD in children is CyA for adolescents over 16 years. Vaccinations, including those against measles in hen's egg allergy are safe, 176 the only restriction being the quality of skin care to avoid superinfection at injection sites and with vaccination against influenza and yellow fever in highly sensitized egg-allergic children. Vaccinations especially against varicella are recommended to avoid severe cutaneous viral infections.
Educational programmes and counselling
AD has a major impact on the quality of life of patients and caregivers, despite available treatment strategies. Poor adherence to prescribed treatment is frequent and leads to therapeutic failure. There is a significant and urgent need for physicians to ensure that patients with AD are educated and confident in using medication as prescribed to gain disease control. 177 Education is designed to train patients in the skills of self-management or adapting treatment to their particular chronic disease and in coping processes and skills. Educational intervention will help for the management of difficult to treat atopic patients. 44, 171, 178 In the last decade, educational programmes for patients and parents with AD were established in different European countries. Standardized interdisciplinary programmes involving dermatologists, paediatricians, psychologists, psychosomatic counsellors and dietary counselling have been demonstrated to improve subjective and objective symptoms, optimize medication use in patients and result in a significant gain in quality of life. 170, 179 Participation in one of these programmes is highly encouraged. Low social support and highly active problem-solving behaviour improves the interest to take part in patient education programmes at least for childhood atopic dermatitis. 180 Recently, an international group of experts in this field has published a position paper on the objectives and recommendations on therapeutic education for AD patients and their parents, 181 which includes useful and avoidable measures.
Worldwide experiences demonstrate an increased interest in therapeutic education for managing AD patients and show that individual and collective approaches can be used.
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In addition to the provision of correct information and the correction of misinformation, physicians must address barriers to adherence with AD treatment, such as parent anxiety about the safety of TCS and TCS. Therapeutic education should be integrated in the treatment of AD. Support materials for healthcare professionals and for parents can be found on >www.fondation-dermatite-atopique.org<.
